For patients undergoing diagnostic cardiac catheterization or peripheral angiography utilizing femoral artery access, the D-Stat Dry bandage is safe and effective in reducing both time-to-hemostasis (TTH) and time-to-ambulation (TTA) and results in improved patient satisfaction, according to a study published in the July/August issue of CardioVascular and Interventional Radiology.
Five sites participated in the study: Charleston Area Medical Center in West Virginia; Abbott Northwestern in Minneapolis; Tri-Health (Good Samaritan/Bethesda) in Cincinnati; Mount Sinai Medical Center in Miami; and Terrebonne General Medical Center in Houma, La.
The prospective, randomized U.S. study examined 376 subjects (189 control, 187 investigational) with similar baseline characteristics. The mean age was 61.5 years, and the male predominance was 58 percent.
The researchers found that TTH was significantly lower in the investigational group (7.8 vs. 13.0 min). No difference in major complication rates was observed between the groups. The mean TTA (investigational, 392 min, vs. control, 415 min) and patient satisfaction significantly favored the investigational group. No difference in TTD or the rate of minor complications was observed.
The Minneapolis-based Vascular Solutions is the manufacturer of thrombin-based D-Stat Dry hemostatic bandages.